Compare Celsius Holdings, Inc. (CELH) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celsius Holdings, Inc. vs Medpace Holdings Inc — how do they compare? Celsius Holdings, Inc. trades at $27.4 (market cap $7.11B), while Medpace Holdings Inc trades at $598.37 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 2.4× Celsius Holdings, Inc.'s market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Celsius Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| CELH | MEDP | |
|---|---|---|
Market Cap | $7.11B | $16.90B |
Sector | Consumer Staples | Technology |
52-Week High | $64.86 | $620.59 |
52-Week Low | $23.77 | $393.42 |
Enterprise Value | $8.90B | $16.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CELH trades at $27.37, up 0.59% on the day, but its technical outlook is bearish with key support at $26. Revenue growth remains strong, reaching $2.52B in 2025, though net income margins have compressed to 4.24%. The company faces headwinds from a recent earnings miss and core brand weakness, but maintains a robust 95.65% analyst buy rating with a $44.08 consensus price target.
The stock offers significant upside potential based on analyst targets, but risks include execution challenges, intense competition, and margin pressure. Investor sentiment is cautious due to slowing growth and leadership changes, yet the long-term growth story, supported by the PepsiCo partnership, remains intact for patient investors.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
